If you are already in a non-clinical field, do non-clinical consulting, or are considering a non-clinical career change, watching FDA approvals can be helpful as a guide for areas of future hiring and support needs.
According to Fiercebiotech, 6 biologics and 15 small molecule drugs passed FDA inspection last year. The success was evenly distributed through the industry, with no drugmaker in 2010 having more than one new drug approved. A list of 2010 CBER approvals, such as Provenge and Prevnar-13, can be found on their website.
